Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: fukuda h. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
Fujii T, Kunikane H, Okamoto H, Watanabe K, Kunitoh H, Mori K, Yokoyama A, Fukuda H, Tamura T, Saijo N. Fujii T, et al. Among authors: fukuda h. Jpn J Clin Oncol. 2009 Dec;39(12):784-90. doi: 10.1093/jjco/hyp102. Epub 2009 Sep 20. Jpn J Clin Oncol. 2009. PMID: 19770129 Clinical Trial.
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Atagi S, et al. Among authors: fukuda h. Lancet Oncol. 2012 Jul;13(7):671-8. doi: 10.1016/S1470-2045(12)70139-0. Epub 2012 May 22. Lancet Oncol. 2012. PMID: 22622008 Clinical Trial.
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Satouchi M, et al. Among authors: fukuda h. J Clin Oncol. 2014 Apr 20;32(12):1262-8. doi: 10.1200/JCO.2013.53.5153. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24638015 Clinical Trial.
Current status and future perspectives of cooperative study groups for lung cancer in Japan.
Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y. Kawano Y, et al. Among authors: fukuda h. Respir Investig. 2014 Nov;52(6):339-47. doi: 10.1016/j.resinv.2014.06.004. Epub 2014 Jul 24. Respir Investig. 2014. PMID: 25453377 Review.
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T, Takii Y, Ojima H, Masuko H, Kubo Y, Mishima H, Yamaguchi T, Bando H, Sato T, Kato T, Nakamura K, Fukuda H, Moriya Y. Hamaguchi T, et al. Among authors: fukuda h. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56. doi: 10.1016/S2468-1253(17)30297-2. Epub 2017 Oct 24. Lancet Gastroenterol Hepatol. 2018. PMID: 29079411 Clinical Trial.
Prognostic value ​of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803/WJOG4307L (JCOG1414A).
Mizutani T, Ando M, Mizusawa J, Nakamura K, Fukuda H, Tsukada H, Abe T, Takeda K, Yokoyama A, Nakamura S, Nakagawa K, Yamamoto N, Ohe Y. Mizutani T, et al. Among authors: fukuda h. J Geriatr Oncol. 2018 Nov;9(6):583-588. doi: 10.1016/j.jgo.2018.04.005. Epub 2018 May 3. J Geriatr Oncol. 2018. PMID: 29731344 Clinical Trial.
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
Hashimoto H, Abe M, Yanai T, Yamaguchi T, Zenda S, Uchitomi Y, Fukuda H, Mori M, Iwasa S, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: fukuda h. Jpn J Clin Oncol. 2018 Oct 1;48(10):950-952. doi: 10.1093/jjco/hyy114. Jpn J Clin Oncol. 2018. PMID: 30124989 Clinical Trial.
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Yoshikawa T, et al. Among authors: fukuda h. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22. Lancet Gastroenterol Hepatol. 2019. PMID: 30679107 Clinical Trial.
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.
Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Yamada Y, et al. Among authors: fukuda h. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. doi: 10.1016/S2468-1253(19)30083-4. Epub 2019 May 14. Lancet Gastroenterol Hepatol. 2019. PMID: 31101534 Clinical Trial.
3,605 results